In fact, the neutralization of IL-17A, either by antibody treatment or by genetic ablation, leads to exacerbated intestinal inflammation in the dextran sulphate sodium (DSS) colitis model [55, 56], which is typically associated with intestine epithelial barrier dysfunction and increased permeability to luminal agents that promote the inflammatory response [57]. Here, IL17A is linked to colitis.